FindTrial
Sign In

COMPARISION OF TWO DRUGS FOR FEMORAL NERVE BLOCK

Evaluation of Post-Operative Analgesia: On Addition of Dexmedetomidine to Ropivacaine 0.2% For Femoral Nerve Block in Patients Undergoing Open Knee Surgery- A randomized single blind study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/09/015782
Enrollment
60
Registered
2018-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- American Society of Anaesthesiology physical Status I and II

Interventions

Intervention1: Dexmedetomidine: Ropivacaine 0.2% 20 ml + Dexmedetomidine(50 microgram),intraneural ,postoperative one time Control Intervention1: Ropivacaine: Ropivacaine 0.2% 20 ml + normal saline

Sponsors

Medical college Baroda Vadodara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA- I/II Malampatti Grade-I/II Weight: 40 to 70 kgs Open Knee Surgeries

Exclusion criteria

Exclusion criteria: ASA- III/IV Patients with coagulopathy, local infection and pre-existing neuropathy Hypersensitivity to local anaesthetic drug Patients with h/o drug abuse or psychiatric illness

Design outcomes

Primary

MeasureTime frame
1.To compare the duration of analgesia 2.To Compare the mean cumulative requirement of systemic analgesic post-operatively till 24 hours post-femoral nerve block.Timepoint: 1.To compare the duration of analgesia at 2 4 6 8 10 12 16 20 24 hours postoperatively 2.To Compare the mean cumulative requirement of systemic analgesic post-operatively at 2 4 6 8 10 12 16 20 24 hours post-femoral nerve block—

Secondary

MeasureTime frame
1.Assesment of sedation 2.To evaluate intra and post-operative complaints if anyTimepoint: at 2 4 6 8 10 12 16 20 24 hours post femoral nerve block—

Countries

India

Contacts

Public ContactDr Neha Shah

Medical college baroda

jayeshkatakiya83@gmail.com09727376693

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026